Incidence, mortality, and survival of hematological malignancies in Northern Italian patients: an update to 2020

Frontiers in Oncology

Oncology

Fortunato Morabito¹  Claudia Vener²  Paolo Giorgi Rossi³  Lucia Mangone³  Francesca Roncaglia³  Francesco Marinelli³  Isabella Bisceglia³  Alessia Ruffini⁴  Barbara Gamberi⁵  Francesco Merli⁵  Alessia Tieghi⁵  Stefano Luminari⁶  Laura Albertazzi⁷  Mauro Iori⁸  Riccardo Valli⁹  Domenico Penna^1,10  Antonino Neri^1,11 

[1] Biotechnology Research Unit, AO di Cosenza, Cosenza, Italy;Department of Oncology and Hemato-oncology, Università di Milano, Milano, Italy;Epidemiology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy;Gruppo Amici Dell’Ematologia Foundation-GrADE, Reggio Emilia, Italy;Hematology Unit, Azienda USL- IRCCS di Reggio Emilia, Reggio Emilia, Italy;Hematology Unit, Azienda USL- IRCCS di Reggio Emilia, Reggio Emilia, Italy;Chimomo Department, University of Modena and Reggio Emilia, Reggio Emilia, Italy;Laboratory of Clinical Chemistry, Azienda USL- IRCCS di Reggio Emilia, Reggio Emilia, Italy;Medical Physics Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy;Pathology Unit, Azienda USL- IRCCS di Reggio Emilia, Reggio Emilia, Italy;PhD Program in Clinical and Experimental Medicine, University of Modena and, Reggio Emilia, Italy;Scientific Directorate, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy;

关键词: hematological malignancies;    incidence;    mortality;    survival;    trends;    cancer registry;    digital health;   

DOI  :  10.3389/fonc.2023.1182971

 received in 2023-03-09, accepted in 2023-06-15,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundHematological malignancies (HMs) represent a heterogeneous group of diseases with diverse etiology, pathogenesis, and prognosis. HMs’ accurate registration by Cancer Registries (CRs) is hampered by the progressive de-hospitalization of patients and the transition to molecular rather than microscopic diagnosis.Material and methodsA dedicated software capable of automatically identifying suspected HMs cases by combining several databases was adopted by Reggio Emilia Province CR (RE-CR). Besides pathological reports, hospital discharge archives, and mortality records, RE-CR retrieved information from general and biomolecular laboratories. Incidence, mortality, and 5-year relative survival (RS) reported according to age, sex, and 4 HMs’ main categories, were noted.ResultsOverall, 7,578 HM cases were diagnosed from 1996 to 2020 by RE-CR. HMs were more common in males and older patients, except for Hodgkin Lymphoma and Follicular Lymphoma (FL). Incidence showed a significant increase for FL (annual percent change (APC)=3.0), Myeloproliferative Neoplasms (MPN) in the first period (APC=6.0) followed by a significant decrease (APC=-7.4), and Myelodysplastic Syndromes (APC=16.4) only in the first period. Over the years, a significant increase was observed in 5-year RS for Hodgkin -, Marginal Zone -, Follicular - and Diffuse Large B-cell-Lymphomas, MPN, and Acute Myeloid Leukemia. The availability of dedicated software made it possible to recover 80% of cases automatically: the remaining 20% required direct consultation of medical records.ConclusionsThe study emphasizes that HM registration needs to collect information from multiple sources. The digitalization of CRs is necessary to increase their efficiency.

【 授权许可】

Unknown   
Copyright © 2023 Mangone, Penna, Marinelli, Roncaglia, Bisceglia, Merli, Ruffini, Gamberi, Tieghi, Valli, Albertazzi, Iori, Giorgi Rossi, Vener, Morabito, Neri and Luminari